Key Highlights

  • Merck shares are trading at $147.86 in Wednesday's session, down 2.02%.
  • A research firm downgraded the stock, calling shares Overvalued and overbought after a roughly 92% run since mid-2025.
  • The pullback comes despite recent pipeline wins, including an FDA label update for Winrevair and CHMP backing for a Keytruda combination.
  • Analysts maintain a consensus rating around Moderate Buy, with one firm raising its price target to $155.

Investors Take Profits on Valuation Concerns

Merck (NYSE:MRK) shares are pulling back in Wednesday's session after a research firm downgraded the stock, arguing shares look overvalued and overbought following a strong rally dating back to mid-2025. The firm pointed to a trailing price-to-earnings ratio above 120 despite only mid-single-digit Revenue growth as a reason for caution, even as the company continues to notch pipeline progress.

Despite the downgrade, the pullback comes even as Merck continues to post positive clinical and regulatory news. The company recently secured an FDA label update for Winrevair based on Phase 3 data, along with European CHMP backing for a Keytruda combination regimen, developments that would typically be read as supportive rather than negative for the stock.

A Broad Pharmaceutical and Animal Health Portfolio

Merck is a global healthcare leader operating through two core segments, Pharmaceuticals and Animal Health, delivering medicines, vaccines, biologic therapies and veterinary products. Its pharmaceutical segment spans oncology, immunology, virology, cardiovascular disease, diabetes and neuroscience, alongside preventive vaccines for pediatric, adolescent and adult populations. The company generates over $65 billion in annual revenue and employs approximately 74,000 people worldwide.

Reliance on Keytruda Weighs on Sentiment

One Factor feeding into today's valuation debate is Merck's heavy reliance on Keytruda, which accounts for over half of total sales, raising questions about the durability of growth as the company works to diversify its pipeline ahead of the drug's eventual Patent cliff. A separate research desk raised its price target to $155 with a Hold rating, while analysts overall maintain a consensus Moderate Buy with an average price target near $154. The company recently completed a roughly $5.7 billion oncology acquisition, a move aimed at broadening its pipeline beyond its current flagship therapy.